Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT02588625 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02588625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02588625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Withdrawn
Start date
February 29, 2016
Completion date
October 31, 2019
Enrollment
0 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma